Proposed Thresholds for Pancreatic Tissue Volume for Safe Intraportal Islet Autotransplantation After Total Pancreatectomy von Wilhelm, J. J., Bellin, M. D., Dunn, T. B., Balamurugan, A. N., Pruett, T. L., Radosevich, D. M., Chinnakotla, S., Schwarzenberg, S. J., Freeman, M. L., Hering, B. J., Sutherland, D. E. R., Beilman, G. J.

Volltext

Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: A consensus conference report von Moran, A., Hardin, D., Rodman, D., Allen, H.F., Beall, R.J., Borowitz, D., Brunzell, C., Campbell III, P.W., Chesrown, S.E., Duchow, C., Fink, R.J., Fitzsimmons, S.C., Hamilton, N., Hirsch, I., Howenstine, M.S., Klein, D.J., Madhun, Z., Pencharz, P.B., Quittner, A.L., M.K., Robbins, Schindler, T., Schissel, K., Schwarzenberg, S.J., Stallings, V.A., Tullis, D.E., Zipf, W.B.

Volltext

Clinical and Biochemical Findings in Progressive Familial Intrahepatic Cholestasis von Whitington, Peter F., Freese, Deborah K., Alonso, Estella M., Schwarzenberg, S. Jane, Sharp, Harvey L.

Volltext

598 Elexacaftor/tezacaftor/ivacaftor does not improve pancreatic function in people with CF aged 12 and older: Report of PROMISE GI at 30 months von Schwarzenberg, S., Vu, P., Gelfond, D., Hoffman, L., Narkewicz, M., Freedman, S.

Volltext

599 Elexacaftor/tezacaftor/ivacaftor (ETI) does not improve indices of hepatic fibrosis, liver stiffness, or hepatic steatosis after 3 years: interim results of the PROMISE study von Narkewicz, M., Johnson, D., Schwarzenberg, S., Freedman, S., Green, N., Wagner, B.

Volltext

619 Multicenter Study of Non-invasive Colorectal Cancer Evaluation in Cystic Fibrosis (NICE-CF) von Hachem, C., Freedman, S., Schwarzenberg, S., Stukovsky, K. Hinckley, Tressel, W., Joyeux, C.

Volltext

209: Elexacaftor/tezacaftor/ivacaftor alters gastrointestinal symptoms: Six-month report of PROMISE GI von Schwarzenberg, S., Vu, P., Skalland, M., Freedman, S.

Volltext

579 Lipid concentrations after 12 to 18 months of clinically prescribed elexacaftor tezacaftor ivacaftor—PROMISE substudy von Bass, R., Stalvey, M., Nichols, D., Rowe, S., Schwarzenberg, S., Freedman, S., Solomon, G., Kelly, A.

Volltext

609 Effect of elexacaftor/tezacaftor/ivacaftor on gastrointestinal pH and motility in adults with CF: results from PROMISE von Patel, D., Sadauskas, M., Frederick, C., Hoffman, L., Freedman, S., Narkewicz, M., Schwarzenberg, S., Solomon, G., Gelfond, D., Sellers, Z.

Volltext

540 Impact of elexacaftor-tezacaftor-ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function, and fat malabsorption: Report of PROMISE PEDS GI von Green, N., Vu, P., Schwarzenberg, S., Freedman, S., Narkewicz, M., Pittman, J., Ratjen, F., Rosenfeld, M., Lusman, S.

Volltext

658 Longitudinal changes in bone mineral density in adolescents and adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor—results from the PROMISE study von Kindler, J., Zemel, B., Bezerra, M. Shirley, Walega, R., Schwarzenberg, S., Freedman, S., Stalvey, M., Solomon, G., Chan, C., Kelly, A.

Volltext

51 Prevalence of Clostridioides difficile in people with cystic fibrosis participating in the PROMISE Study before and after initiating elexacaftor/tezacaftor/ivacaftor von Gill, E., Duong, J., Pope, C., Hayden, H., Verster, A., Hoffman, L., Schwarzenberg, S., Heltshe, S., Solomon, G., Freedman, S., Goss, C.

Volltext

224 Elexacaftor/tezacaftor/ivacaftor alters gastrointestinal symptoms and inflammation: Report of PROMISE Pediatric Gastrointestinal Study von Green, N., Vu, P., Skalland, M., Schwarzenberg, S., Freedman, S., Pittman, J., Ratjen, F., Rosenfeld, M., Lusman, S.

Volltext

Morbidity from Congenital Hepatic Fibrosis after Renal Transplantation for Autosomal Recessive Polycystic Kidney Disease von Khan, Khalid, Schwarzenberg, Sara Jane, Sharp, Harvey L., Matas, Arthur J., Chavers, Blanche M.

Volltext

635 Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF (STRONG-CF): a study protocol von Alvarez, J., Putman, M., Stein, A., Sibayan, J., Enos, M., Sabean, A., Riekert, K., Larson-Nath, C., Clancy, J., Riva, D., Khan, U., Reed, Z., Fults, A., Davis, J., Freedman, S., Schwarzenberg, S.

Volltext

206: Gastrointestinal symptoms are common in people with cystic fibrosis regardless of gastrointestinal medication usage: Results from GALAXY von Moshiree, B., Freeman, J., Vu, P., Khan, U., Heltshe, S., Goss, C., Schwarzenberg, S., Freedman, S., Sathe, M.

Volltext

Optimizing bone health in children and adolescents von Golden, Neville H, Abrams, Steven A

Volltext

Cystic fibrosis–associated colitis and fibrosing colonopathy von Schwarzenberg, S.J., Wielinski, C.L., Shamieh, I., Carpenter, B.L.M., Jessurun, J., Weisdorf, S.A., Warwick, W.J., Sharp, H.L.

Volltext

Fruit Juice in Infants, Children, and Adolescents: Current Recommendations von Heyman, Melvin B, Abrams, Steven A

Volltext

The Effects of Early Nutritional Interventions on the Development of Atopic Disease in Infants and Children: The Role of Maternal Dietary Restriction, Breastfeeding, Hydrolyzed For... von Greer, Frank R, Sicherer, Scott H, Burks, A Wesley

Volltext